Kirill Dmitriev, the Chief Executive Officer of  Russian Direct Investment Fund (RDIF) announced on 25th June, 2020 about its prospects of financing more Favipiravir-based drugs.

He stated, “Two more pharmaceuticals are settling the clinical trials of favipiravir-based drugs in Russia which will effectively produce favipiravir-based drugs. We support those companies and plan to invest its production for these medicines.” Clinical trials of Favipiravir are presently ongoing throughout the world; especially a leading pharma company of India has already obtained registration, while Turkey is undertaking registration now, CEO told. Earlier in June, the first Favipiravir-based drug, Avifavir by RDIF and ChemRar Group has been approved for COVID-19 treatment with high efficiency in clinical trials. With its delivery in Russian hospitals initiated on 11, June, its test batches have also been delivered to Belarus.